Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04607980 · ClinicalTrials.gov registry record · Phase 3
A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
A Phase 3 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 563
- Enrollment target
NCT04607980 is a Phase 3 study that has completed, run by Amgen. The registered enrollment target is 563 participants.
The verdict
NCT04607980, a Phase 3 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 563 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the efficacy, safety, and immunogenicity of ABP 654 compared with ustekinumab in participants with moderate to severe plaque psoriasis.
Interventions
- DRUG Ustekinumab
- DRUG ABP 654
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 563 participants |
| Start Date | 2020-11-11 |
| Est. Completion | 2022-06-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04607980
The ClinicalTrials.gov registry entry for NCT04607980 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 563 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ustekinumab is the first listed.
NCT04607980 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04607980 about?
NCT04607980 is a clinical study titled "A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis". The purpose of the study is to evaluate the efficacy, safety, and immunogenicity of ABP 654 compared with ustekinumab in participants with moderate to severe plaque psoriasis.
What is the current status of trial NCT04607980?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 563 participants. The study started on 2020-11-11. Estimated completion is 2022-06-03.
What interventions are being tested in trial NCT04607980?
The interventions under investigation include: Ustekinumab (DRUG), ABP 654 (DRUG).
Who is sponsoring clinical trial NCT04607980?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.